The airway smooth muscle (ASM) cell is the final effector of both bronchoconstriction and bronchodilation. Its contractile state is determined by intracellular second-messenger balance: the concentration of calcium and the phosphorylation state of myosin light chain (MLC). All bronchodilator drug classes act by shifting this balance toward relaxation, and all bronchoconstrictor pathways act by shifting it toward contraction. A precise understanding of these signaling cascades directly predicts which receptor subtypes are therapeutic targets, which are bystanders, and which, when inadvertently activated, produce adverse effects.
Bronchoconstriction is driven primarily through the Gq-coupled receptor signaling pathway. When agonists such as acetylcholine, histamine, or leukotrienes bind to their respective Gq-linked receptors on ASM, phospholipase C (PLC) is activated, cleaving phosphatidylinositol 4,5-bisphosphate (PIP2) into two second messengers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 acts on IP3 receptors on the sarcoplasmic reticulum to release stored calcium, raising intracellular calcium concentration. DAG, in concert with elevated calcium, activates protein kinase C (PKC). The calcium/calmodulin complex activates myosin light chain kinase (MLCK), which phosphorylates MLC, driving cross-bridge cycling and ASM contraction.1 This pathway is the molecular basis for the bronchoconstriction produced by acetylcholine acting at M3 muscarinic receptors and by cysteinyl leukotrienes acting at CysLT1 receptors on ASM.
Bronchodilation is driven through the opposing Gs/adenylyl cyclase/cyclic AMP (cAMP)/protein kinase A (PKA) axis. When beta-2 adrenergic receptors on ASM are activated by catecholamines or synthetic beta-2 agonists, the associated Gs protein activates adenylyl cyclase (AC), increasing intracellular cAMP. Elevated cAMP activates PKA, which phosphorylates MLCK to reduce its activity and also directly phosphorylates MLC phosphatase to increase its activity, shifting the net balance away from MLC phosphorylation and toward ASM relaxation. PKA additionally activates large-conductance calcium-activated potassium channels (BKCa), hyperpolarizing the cell membrane and reducing calcium entry through voltage-gated calcium channels.1 The resultant fall in intracellular calcium and reduction in MLC phosphorylation state allows myosin-actin cross-bridges to dissociate and the muscle to relax.
The muscarinic receptor system in the airways involves three receptor subtypes with distinct locations and functional roles. M1 receptors are located on parasympathetic ganglia in the airway wall and on the surface of the airway epithelium; their activation facilitates ganglionic neurotransmission, augmenting overall parasympathetic tone to the airway. M2 receptors are located presynaptically on postganglionic parasympathetic nerve terminals and function as autoreceptors: when activated by acetylcholine, they inhibit further acetylcholine release through a Gi-coupled negative feedback mechanism. M3 receptors are the primary effectors of bronchoconstriction; they are located on airway smooth muscle and submucosal glands, where their activation via Gq produces both bronchoconstriction and increased mucus secretion.2 This subtype distribution has important implications for anticholinergic drug design: an ideal bronchodilator would block M1 and M3 while sparing M2, since M2 blockade would remove the autoreceptor brake and potentially increase acetylcholine release, partially offsetting the M3-blocking benefit.
Phosphodiesterase (PDE) enzymes are responsible for cAMP degradation, and their inhibition therefore sustains bronchodilation. Two PDE isoforms are particularly relevant to pulmonary pharmacology. PDE3, expressed in ASM and cardiac muscle, hydrolyzes cAMP and also cGMP (cyclic GMP); its inhibition in ASM prolongs cAMP elevation and sustains bronchodilation. PDE4 is the predominant cAMP-metabolizing phosphodiesterase in inflammatory cells including neutrophils, eosinophils, mast cells, and macrophages; its inhibition reduces inflammatory mediator release in addition to producing some bronchodilation.1 This distinction explains why selective PDE4 inhibitors such as roflumilast are used primarily for their anti-inflammatory effects in COPD (chronic obstructive pulmonary disease) rather than as bronchodilators, whereas older non-selective PDE inhibitors such as theophylline produce bronchodilation through a combination of PDE3 and PDE4 inhibition plus adenosine receptor antagonism.
The nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cyclic GMP (cGMP) pathway provides a third bronchodilatory axis, distinct from the cAMP pathway. Nitric oxide produced by constitutive nitric oxide synthase (NOS) in airway epithelial and endothelial cells diffuses into adjacent ASM, where it activates sGC to produce cGMP. Elevated cGMP activates protein kinase G (PKG), which reduces intracellular calcium and inhibits MLCK, producing ASM relaxation.3 PDE5 degrades cGMP in smooth muscle; the bronchodilatory relevance of the NO/cGMP pathway in clinical practice is primarily seen in the setting of pulmonary arterial hypertension, where PDE5 inhibitors such as sildenafil are therapeutic agents. In asthma, exhaled NO is elevated in eosinophilic airway inflammation and serves as a biomarker (fractional exhaled NO, FeNO) rather than a therapeutic target at present.
Bronchoconstriction: Gq-coupled receptors (M3 muscarinic, CysLT1, H1 histamine) activate phospholipase C (PLC) to generate IP3 (inositol 1,4,5-trisphosphate) and DAG (diacylglycerol). IP3 releases sarcoplasmic reticulum calcium; elevated calcium activates myosin light chain kinase (MLCK), driving contraction. Bronchodilation: Gs-coupled beta-2 adrenergic receptors activate adenylyl cyclase (AC), raising cAMP (cyclic AMP), activating PKA (protein kinase A), which inactivates MLCK and activates myosin light chain phosphatase. PDE3 and PDE4 degrade cAMP, limiting the bronchodilatory response; PDE inhibition prolongs it.
Short-acting beta-2 agonists (SABAs) are the oldest class of inhaled bronchodilators and remain the standard of care for acute bronchospasm across all obstructive lung diseases. Their rapid onset of action, well-characterized adverse effect profile, and clinical efficacy in acute bronchoconstriction make them indispensable in both scheduled and rescue contexts. Understanding their receptor selectivity, the pharmacological differences between racemic and single-enantiomer formulations, and the physiological basis of their systemic adverse effects is essential for rational prescribing.
Albuterol (also known as salbutamol outside North America) is the prototype SABA and the most widely prescribed bronchodilator globally. It is a selective beta-2 adrenergic receptor agonist with approximately 200-fold selectivity for beta-2 over beta-1 receptors at therapeutic doses, though this selectivity is not absolute and diminishes at higher doses or plasma concentrations. Albuterol is commercially available as a racemic mixture of R- and S-enantiomers in equal proportions. The R-enantiomer, (R)-albuterol, is the pharmacologically active form responsible for bronchodilation; it binds beta-2 receptors with high affinity and activates the Gs/cAMP (cyclic AMP)/PKA (protein kinase A) signaling cascade. The S-enantiomer, (S)-albuterol, binds beta-2 receptors with substantially lower affinity and does not contribute meaningfully to bronchodilation. Inhaled racemic albuterol has an onset of action of 5 to 15 minutes and a duration of 4 to 6 hours, making it suitable for as-needed rescue use and for pre-exercise prophylaxis against exercise-induced bronchoconstriction (EIB).4
Levalbuterol is the isolated R-enantiomer of albuterol marketed as a single-isomer formulation. The theoretical rationale for levalbuterol is that by eliminating the S-enantiomer, the delivered dose of pharmacologically active drug is higher at a given total milligram dose, potentially reducing systemic adverse effects that are driven by total drug exposure while maintaining bronchodilatory efficacy. Clinical trial evidence on this question is mixed. The S-enantiomer is cleared more slowly than the R-enantiomer, so with repeated doses of racemic albuterol the S/R ratio in plasma rises over time. Some investigators proposed that accumulating S-albuterol might promote airway hyperresponsiveness or bronchoconstriction through non-beta-2 mechanisms, but clinical studies have not consistently demonstrated a clinically meaningful advantage for levalbuterol over equivalent doses of racemic albuterol in terms of bronchodilation, hospitalization rates, or adverse effect incidence in acute asthma.5 Levalbuterol is approximately twice the cost of racemic albuterol. Current guidelines do not preferentially recommend levalbuterol over racemic albuterol.
Terbutaline is a second SABA with a pharmacological profile similar to albuterol. In the United States it is available for subcutaneous administration, where it is used for acute severe asthma when inhaled bronchodilators cannot be delivered effectively. It is also used parenterally as a uterine tocolytic, exploiting the beta-2-mediated relaxation of uterine smooth muscle. In countries where terbutaline is available as a dry powder inhaler, it serves as a rescue bronchodilator comparable to albuterol. Its duration of action and adverse effect profile are similar to those of albuterol. Unlike albuterol, terbutaline is not available as a metered-dose inhaler in the United States, limiting its use in that market to the parenteral setting.4
The systemic adverse effects of SABAs reflect stimulation of beta-2 receptors in tissues outside the airway. Skeletal muscle tremor is the most common adverse effect of inhaled SABAs; it results from beta-2 receptor-mediated activation of slow-twitch muscle fibers and is most pronounced with higher doses or systemic administration. Tachycardia occurs through two mechanisms: direct cardiac beta-1 stimulation (imperfect beta-2 selectivity at therapeutic doses) and reflex tachycardia secondary to beta-2-mediated peripheral vasodilation. Hypokalemia is a clinically important metabolic effect: beta-2 receptor activation increases the activity of the Na-K-ATPase pump in skeletal muscle, driving potassium into cells and lowering serum potassium. The magnitude of this effect is dose-dependent and most pronounced with systemic or high-dose nebulized administration; serum potassium may fall by 0.5 to 1.0 mEq/L with standard nebulized doses and more substantially with continuous nebulization.4 Hyperglycemia occurs through beta-2-mediated stimulation of glycogenolysis in the liver and inhibition of insulin secretion from pancreatic beta cells.
In acute severe asthma requiring high-dose or continuous nebulized albuterol, monitor serum potassium, cardiac rhythm, and blood glucose. Hypokalemia is additive with systemic corticosteroids and loop diuretics commonly used in acute asthma management. Tachycardia alone in this context does not indicate SABA toxicity; it may reflect the underlying acute asthma physiology (hypoxia, adrenergic response) rather than drug effect. Tremor is the most reliable dose-dependent marker of systemic beta-2 exposure. In patients with known coronary artery disease, the combination of tachycardia and hypokalemia warrants monitoring.
Long-acting beta-2 agonists (LABAs) are defined by a duration of action of at least 12 hours, distinguishing them from SABAs (short-acting beta-2 agonists) pharmacokinetically and clinically. Within the LABA class, however, there are pharmacologically significant differences in onset of action, intrinsic efficacy at the beta-2 receptor, and mechanism of prolonged duration. These differences have direct clinical implications: they determine which LABAs are suitable for rescue use in addition to maintenance dosing, and they shaped the design and interpretation of the major safety trials that redefined how LABAs are used in asthma.
Salmeterol is a partial agonist at the beta-2 adrenergic receptor and the prototypical LABA in clinical use. Its prolonged duration is explained by the lipophilic side chain of the molecule, which anchors it in the lipid bilayer of the plasma membrane adjacent to the receptor (the "membrane depot" or "exosite" mechanism). From this membrane reservoir, salmeterol rebinds the orthosteric binding site repeatedly over time, producing sustained receptor activation without requiring continuous high extracellular drug concentrations. As a partial agonist, salmeterol produces less maximal bronchodilation than a full agonist and has a slow onset of action of 10 to 20 minutes, which is too slow for reliable relief of acute bronchoconstriction. Salmeterol should not be used as a rescue agent. Its duration of action is approximately 12 hours, appropriate for twice-daily maintenance dosing.2
Formoterol is a full agonist at the beta-2 receptor and differs from salmeterol in two pharmacologically consequential ways. First, its onset of action is 1 to 3 minutes after inhalation, comparable to albuterol, making it the only LABA with a rapid enough onset to serve as a rescue bronchodilator. Second, as a full agonist it produces greater maximal bronchodilation per unit receptor occupancy than salmeterol. Formoterol's prolonged duration reflects its high lipophilicity and a different interaction with the receptor than salmeterol, but the net result is similar 12-hour duration. These pharmacological properties are the basis of the SMART (Single Maintenance And Reliever Therapy) strategy, in which budesonide/formoterol is used as both the daily maintenance controller and the as-needed reliever, eliminating the need for a separate SABA.12 This approach, validated in the SYGMA 1 and SYGMA 2 trials, reduces exacerbation rates compared with SABA-only rescue in mild asthma and is now incorporated into GINA (Global Initiative for Asthma) 2024 guidance as an option at all steps of the asthma treatment ladder.
Ultra-long-acting beta-2 agonists represent a pharmacologically distinct subclass with durations exceeding 24 hours, making once-daily dosing practical. Indacaterol (available in the United States in a fixed-dose combination with glycopyrrolate) is a full agonist with onset of action within 5 minutes and duration of approximately 24 hours. Olodaterol (available in fixed-dose combination with tiotropium as Stiolto Respimat) and vilanterol (available in fixed-dose combinations with umeclidinium or fluticasone furoate) are also ultra-LABAs approved for once-daily dosing. All three are approved for COPD (chronic obstructive pulmonary disease) only in the United States; none are approved as monotherapy for asthma. The once-daily dosing of ultra-LABAs confers a substantial adherence advantage in COPD, where the disease is chronic and symptom burden is present throughout the waking day.2
The LABA black box warning in asthma has a specific historical origin and a specific current context that clinicians must understand precisely. The SMART trial (Salmeterol Multicenter Asthma Research Trial) was a large randomized controlled trial comparing salmeterol plus usual care versus placebo plus usual care in asthma patients. The trial was terminated early because of a statistically significant increase in asthma-related deaths and life-threatening asthma events in the salmeterol group, concentrated in African-American patients and in patients not using concomitant inhaled corticosteroids (ICS).2 The mechanistic hypothesis is that LABA monotherapy in asthma may suppress symptoms without controlling underlying eosinophilic airway inflammation, masking deterioration until a life-threatening exacerbation occurs. Following the SMART trial, the FDA required a black box warning for all LABAs in asthma and, subsequently, required that LABAs in asthma be available only in fixed-dose combination with ICS.
The subsequent AUSTRI, STADIA, and VESTRI trials were designed to determine whether the addition of ICS abrogated the LABA safety signal. These trials enrolled asthma patients on ICS and randomized them to ICS plus LABA (formoterol or salmeterol) versus ICS alone, with asthma-related death, intubation, and hospitalization as a composite primary endpoint. None of the three trials demonstrated a statistically significant increase in serious asthma events in the ICS/LABA groups compared with ICS alone.6 On the basis of these trials, the FDA updated LABA labeling in 2017 to remove the most restrictive aspects of the risk evaluation and mitigation strategy (REMS) requirements while retaining the black box warning. The clinical take-away is that LABAs in asthma must always be prescribed with concomitant ICS; LABA monotherapy in asthma remains contraindicated.
Why: The SMART trial demonstrated excess asthma mortality with salmeterol without ICS. LABA monotherapy masks inflammation without controlling it, allowing silent disease progression to fatal exacerbation.
Current standard: LABAs in asthma are prescribed only as fixed-dose ICS/LABA combinations. Prescribing a LABA as a separate inhaler alongside ICS, rather than as a fixed combination, is acceptable but requires explicit patient counseling that both inhalers must be used together at every dose.
COPD exception: LABA monotherapy is appropriate in COPD, where the safety concern from the SMART trial has not been demonstrated and where ICS overuse carries its own risks, particularly pneumonia with fluticasone propionate-containing combinations.
Anticholinergic bronchodilators act by competitively blocking muscarinic receptors on airway smooth muscle and submucosal glands, reducing acetylcholine-mediated bronchoconstriction and mucus hypersecretion. Their mechanism is complementary rather than redundant with beta-2 agonist bronchodilation: they target parasympathetic-driven bronchoconstriction while beta-2 agonists target the smooth muscle relaxation pathway directly. This complementarity is the pharmacological rationale for combining the two classes in both acute management and chronic maintenance therapy.
Ipratropium bromide is the prototypical short-acting muscarinic antagonist (SAMA). It is a quaternary ammonium compound derived from atropine; the quaternary nitrogen imparts a permanent positive charge that prevents significant systemic absorption after inhalation, minimizing central nervous system (CNS) and other systemic anticholinergic effects. Ipratropium blocks M1, M2, and M3 muscarinic receptors without meaningful subtype selectivity. Blockade of M1 receptors at parasympathetic ganglia reduces overall parasympathetic ganglionic transmission; blockade of M3 receptors on ASM (airway smooth muscle) produces bronchodilation; blockade of M2 autoreceptors on postganglionic nerve terminals removes the inhibitory brake on acetylcholine release, partially counteracting the M3 blockade. Despite this M2 blockade limitation, ipratropium produces clinically effective bronchodilation with onset of 15 to 30 minutes and duration of 4 to 8 hours. It is used primarily as a scheduled four-times-daily bronchodilator in COPD (chronic obstructive pulmonary disease) and as a combination agent with albuterol (Combivent) for both COPD and acute asthma management.7
In acute severe asthma, the addition of ipratropium to SABA (short-acting beta-2 agonist) therapy provides additive bronchodilation beyond what can be achieved with albuterol alone. A systematic review and meta-analysis demonstrated that multiple-dose ipratropium combined with beta-2 agonists reduced hospital admissions by approximately 25% in patients with severe acute asthma compared with beta-2 agonists alone, and improved FEV1 (forced expiratory volume in 1 second) to a greater degree than beta-2 agonist monotherapy.7 The mechanism of this additive benefit is precisely the pharmacological complementarity noted above: albuterol acts via cAMP (cyclic AMP), while ipratropium removes parasympathetic bronchoconstriction, and these pathways operate independently on the same smooth muscle cell. Standard dosing for acute asthma combines nebulized ipratropium 0.5 mg with albuterol 2.5 to 5 mg, repeated every 20 minutes for three doses then reassessed.
Tiotropium is the first-generation long-acting muscarinic antagonist (LAMA) and achieves its prolonged duration through kinetic rather than thermodynamic selectivity for M3 over M2 receptors. Tiotropium dissociates from M3 receptors with a half-life of approximately 34.7 hours, while its dissociation from M2 receptors has a half-life of only 3.6 hours. Because tiotropium is given once daily and M3 receptor occupancy is sustained throughout the dosing interval while M2 receptor occupancy is not, the net clinical effect approximates M3 selectivity despite the drug's lack of true receptor affinity selectivity.2 This kinetic distinction from ipratropium is the basis for tiotropium's advantage in sustained 24-hour bronchodilation with once-daily dosing. The TIOSPIR trial evaluated cardiovascular safety of the Respimat soft mist inhaler formulation of tiotropium compared with the HandiHaler dry powder inhaler, specifically addressing concerns that the higher lung-deposited doses from Respimat might increase cardiovascular risk. TIOSPIR demonstrated that the two formulations produced equivalent all-cause mortality and COPD exacerbation rates, confirming the cardiovascular safety of tiotropium Respimat in COPD.8
Second-generation LAMAs include umeclidinium, aclidinium, and glycopyrrolate (also called glycopyrronium in Europe). Umeclidinium (Incruse Ellipta) is a once-daily LAMA with onset of action within 15 minutes and 24-hour duration, approved for COPD maintenance therapy. It is also available in a fixed-dose combination with vilanterol (Anoro Ellipta, a LABA [long-acting beta-2 agonist]/LAMA combination) and in a triple combination with fluticasone furoate and vilanterol (Trelegy Ellipta). Aclidinium (Tudorza Pressair) is approved for twice-daily dosing in COPD; its more rapid dissociation from M3 receptors relative to tiotropium means its clinical benefit does not persist fully with once-daily dosing. Glycopyrrolate (Seebri Breezhaler) is approved for once-daily COPD maintenance and is available in a fixed-dose combination with indacaterol (Utibron Neohaler, also marketed as Ultibro in other markets).2 Revefenacin is a once-daily LAMA approved specifically for nebulizer delivery in COPD, useful in patients unable to use dry powder or metered-dose inhalers reliably.
The class adverse effects of anticholinergic bronchodilators reflect M3 receptor blockade at sites outside the airway. Dry mouth is the most common adverse effect and is reported by up to 16% of patients on tiotropium; it results from reduced salivary gland secretion and is generally mild but may affect tolerance with long-term use. Urinary retention is an important adverse effect in men with benign prostatic hyperplasia (BPH), in whom the reduction in parasympathetic tone to the detrusor muscle may precipitate acute urinary retention; LAMAs should be used with caution in patients with symptomatic BPH and should be discontinued if urinary hesitancy worsens. Acute angle-closure glaucoma is an absolute contraindication to anticholinergic bronchodilators; if the drug mist contacts the eye (particularly relevant with nebulized formulations), it can precipitate acute angle closure in susceptible patients. Constipation reflects reduced parasympathetic tone in the gastrointestinal tract. Systemic CNS anticholinergic effects (confusion, delirium) are rare with inhaled agents because of limited systemic absorption but may be more prominent in elderly patients with reduced renal clearance.2
The SPARK trial compared indacaterol/glycopyrrolate (Ultibro) versus glycopyrrolate alone and versus open-label tiotropium in moderate-to-severe COPD, demonstrating that the LABA/LAMA combination reduced moderate and severe exacerbations more than either single bronchodilator. The FLAME trial demonstrated that indacaterol/glycopyrrolate reduced exacerbation rates compared with salmeterol/fluticasone propionate across the entire COPD population studied, including in patients with high baseline blood eosinophil counts, challenging the previously held assumption that ICS (inhaled corticosteroid)-containing regimens are superior to bronchodilator combinations for exacerbation prevention in all COPD patients.9 Approved once-daily LABA/LAMA combinations in the United States include: umeclidinium/vilanterol (Anoro Ellipta), tiotropium/olodaterol (Stiolto Respimat), glycopyrrolate/formoterol (Bevespi Aerosphere, a pMDI [pressurized metered-dose inhaler]), and glycopyrrolate/indacaterol (Utibron Neohaler/Ultibron).
M1 (ganglionic, epithelial): facilitates parasympathetic ganglionic transmission; blockade reduces overall parasympathetic airway tone.
M2 (presynaptic autoreceptor): inhibits acetylcholine release from postganglionic terminals; blockade removes inhibitory brake, partially counteracting bronchodilation from M3 blockade. Tiotropium's kinetic M3 selectivity minimizes effective M2 blockade during the dosing interval.
M3 (airway smooth muscle and glands): primary target; its blockade reduces bronchoconstriction and mucus hypersecretion. Narrow-angle glaucoma (absolute contraindication) and urinary retention (relative contraindication in BPH) are the most clinically important safety concerns.
The clinical effectiveness of any inhaled bronchodilator is determined not only by its pharmacological profile but also by how much drug actually reaches the lower airways. Inhaled drug delivery is a system involving device design, particle aerodynamics, patient technique, and airway geometry. Prescribers who understand deposition principles can make better device choices for individual patients and can recognize when poor inhaler technique, rather than pharmacological inadequacy, is the primary driver of uncontrolled symptoms.
Lung deposition of inhaled particles is determined primarily by aerodynamic particle size, expressed as mass median aerodynamic diameter (MMAD). Particles with MMAD in the range of 1 to 5 micrometers deposit in the lower airways (bronchi and bronchioles), which is the therapeutic target. Particles larger than 5 micrometers deposit primarily in the oropharynx and are swallowed, contributing to systemic absorption rather than airway drug delivery; this is the primary source of oral candidiasis with inhaled corticosteroids. Particles smaller than 1 micrometer behave like gases, following airflow in and out without depositing on airway surfaces. A lung deposition fraction of 10 to 40% of the nominal dose is typical for standard inhaled drug devices, with the remainder depositing in the oropharynx or being exhaled.10
Pressurized metered-dose inhalers (pMDIs) are propellant-driven devices that generate a bolus aerosol with typical MMADs of 2 to 4 micrometers. Standard pMDI technique requires coordinating the actuation with inhalation, a step that many patients perform incorrectly by actuating before beginning to inhale or by inhaling too rapidly. A valved holding chamber (spacer) eliminates the coordination requirement by allowing the patient to inhale from the chamber at a comfortable rate after actuation. Spacers also decelerate the aerosol plume, allowing larger particles to deposit in the spacer rather than the oropharynx, improving lower airway deposition by 2- to 4-fold compared with an uncoordinated pMDI technique. For inhaled corticosteroids delivered by pMDI, spacer use reduces oropharyngeal deposition and thus reduces the risk of oral candidiasis and dysphonia. Dry powder inhalers (DPIs) are breath-actuated devices that de-aggregate drug powder using the energy of the patient's inspiratory effort; they require a peak inspiratory flow rate of approximately 30 to 60 L/min or higher to achieve adequate de-aggregation and deposition, which may be difficult to achieve in patients with severe airflow obstruction or significant muscle weakness.10 Soft mist inhalers (SMIs), as exemplified by the Respimat device, use mechanical energy from a spring to generate a slow-moving aerosol with a higher fine particle fraction than pMDIs, reducing the dependence on patient coordination or inspiratory effort.
The GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2024 guidelines stratify initial pharmacological management by symptom burden and exacerbation history. GOLD group A patients (low symptoms, low exacerbation risk) are managed with a single bronchodilator, either a SABA (short-acting beta-2 agonist) as needed or a LABA (long-acting beta-2 agonist) or LAMA (long-acting muscarinic antagonist) as maintenance therapy. GOLD group B patients (high symptoms, low exacerbation risk) are initiated on dual bronchodilator therapy with a LABA/LAMA combination as the preferred first-line choice, reflecting the consistent advantage of combination bronchodilation over monotherapy in patients with substantial symptom burden. GOLD group E patients (high exacerbation risk, regardless of symptoms) are initiated on LABA/LAMA combination therapy; ICS-containing triple therapy is considered for group E patients with blood eosinophil counts of 300 cells per microliter or higher, where the anti-inflammatory benefit of ICS is most likely to translate into exacerbation reduction.11 The GOLD 2024 update de-emphasizes FEV1 (forced expiratory volume in 1 second)-based GOLD spirometric grades as the primary driver of pharmacological decision-making, instead prioritizing symptom scores (mMRC dyspnea scale, CAT score) and exacerbation history.
The GINA (Global Initiative for Asthma) 2024 guidelines restructure asthma management around the concept that ICS-containing treatment should be present at every step of the treatment ladder, including in mild asthma. The key change from prior GINA versions is the replacement of SABA-only reliever therapy (at Steps 1 and 2) with ICS/formoterol as the preferred reliever at all steps, including for patients with very mild infrequent symptoms. This recommendation is based on the SYGMA 1 and SYGMA 2 trials (as-needed budesonide/formoterol versus regular budesonide plus as-needed SABA) and the Novel START trial (as-needed budesonide/formoterol versus regular budesonide plus as-needed SABA versus as-needed SABA alone), which collectively demonstrated that as-needed ICS/formoterol reduced severe asthma exacerbations compared with as-needed SABA alone, with adherence-adjusted ICS exposure lower than with scheduled ICS therapy.12 LABA monotherapy in asthma remains absolutely contraindicated regardless of step.
Acute severe asthma management follows a standardized protocol that integrates SABA, SAMA, and systemic corticosteroid therapy. Inhaled short-acting beta-2 agonist (SABA) therapy with albuterol, delivered by pMDI with spacer or nebulizer, is the immediate first-line intervention. Ipratropium (SAMA) is added for acute severe or life-threatening asthma, where its additive bronchodilation through the complementary muscarinic mechanism reduces hospitalization rates. Systemic corticosteroids (oral prednisone or intravenous methylprednisolone) are added for any presentation that does not respond promptly to initial bronchodilator therapy; they reduce airway inflammation over 4 to 6 hours but do not produce acute bronchodilation. Intravenous magnesium sulfate is used in acute severe asthma refractory to initial bronchodilator therapy; its mechanism is inhibition of calcium entry into smooth muscle cells, producing bronchodilation independent of the beta-2 or muscarinic pathways, and it has been shown to reduce admission rates in severe acute asthma when added to standard therapy.4
Asthma (GINA 2024): preferred reliever at all steps is ICS/formoterol (budesonide/formoterol). SABA alone acceptable as reliever if ICS/formoterol not available. LABA is always combined with ICS in asthma; LABA monotherapy is contraindicated. Step-up adds scheduled ICS or ICS/LABA as controller; LABA/LAMA not used in asthma without ICS.
COPD (GOLD 2024): LABA/LAMA combination is the preferred first-line maintenance for most patients with moderate-to-severe COPD. ICS/LABA/LAMA triple therapy is reserved for patients with high exacerbation risk and blood eosinophils 300 cells/mcL or higher. SABA is used for acute symptom relief. LABA monotherapy is appropriate in COPD patients who tolerate LAMA poorly.
Acute severe asthma: high-dose albuterol (SABA) + ipratropium (SAMA) + systemic corticosteroids. Add IV magnesium for inadequate response. Intubation for imminent respiratory failure.
Barnes PJ. Cellular and molecular mechanisms of asthma and COPD. Clin Sci (Lond). 2017;131(13):1541–1558.
doi:10.1042/CS20160487Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504.
doi:10.1124/pr.111.004580Barnes PJ. Nitric oxide and airway disease. Ann Med. 1995;27(3):389–393.
doi:10.3109/07853899509002592Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest. 2004;125(3):1081–1102.
doi:10.1378/chest.125.3.1081Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med. 2005;23(7):842–847.
doi:10.1016/j.ajem.2005.04.003Busse WW, Bateman ED, Caplan AL, et al. Combined analysis of asthma safety trials of long-acting β2-agonists. N Engl J Med. 2018;378(26):2497–2505.
doi:10.1056/NEJMoa1716868Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax. 2005;60(9):740–746.
doi:10.1136/thx.2005.040444Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–1501.
doi:10.1056/NEJMoa1303342Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234.
doi:10.1056/NEJMoa1516385Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377(9770):1032–1045.
doi:10.1016/S0140-6736(10)60926-9Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD executive summary. Eur Respir J. 2023;61(4):2300239.
doi:10.1183/13993003.00239-2023O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–1876.
doi:10.1056/NEJMoa1715274